Drug Trial Radar · NCT02312258
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
706
Actual
Start
Apr 9, 2015
Primary completion
Aug 12, 2019
Study completion Aug 26, 2022
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the effect of ixazomib maintenance therapy on progression free survival (PFS) compared with placebo, in participants with NDMM who have had a major response (complete response \[CR\], very good partial response \[VGPR\], or partial response \[PR\]) to initial therapy and who have not undergone SCT.
Conditions
- Multiple Myeloma
Interventions
PlaceboDrug
Ixazomib placebo-matching capsules.
IxazomibDrug
Ixazomib capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: From randomization until PD or death (up to 52 months)
Locations
275 sites in 35 countries. Site status is shown where the registry gives one.
Robert A Moss MD FACP Inc
Fountain Valley, California
UCLA Medical Hematology and Oncology
Los Angeles, California
North County Oncology Medical Clinic Inc
Oceanside, California
Ventura County Hematology Oncology Specialists
Oxnard, California
Emad Ibrahim, MD, Inc
Redlands, California
Global Cancer Research Institute (GCRI), Inc.
San Jose, California
Central Coast Medical Oncology Corporation
Santa Maria, California
Winship Cancer Institute, Emory University
Atlanta, Georgia
John H. Stroger Jr. Hospital of Cook County
Chicago, Illinois
Siouxland Hematology - Oncology Associates LLP
Sioux City, Iowa
Appalachian Regional Healthcare
Hazard, Kentucky
New England Cancer Specialists
Scarborough, Maine
Saint Agnes Hospital - Baltimore - Hunt - PPDS
Baltimore, Maryland
University Hospital of Wales -
Bethesda, Maryland
Tufts Medical Center - PPDS
Boston, Massachusetts
Herbert-Herman Cancer Center
Lansing, Michigan
Clinical Research Alliance Inc
New York, New York
New York Presbyterian Hospital - Weill-Cornell
New York, New York
Cancer Care of WNC PA
Asheville, North Carolina
UPMC Cancer Pavillion
Pittsburgh, Pennsylvania
HOPE Cancer Center of East Texas
Tyler, Texas
Swedish Cancer Institute
Seattle, Washington
W VA University Mary Babb Randolph Cancer Center
Morgantown, West Virginia
Sanatorio Allende S.A.
Córdoba, Argentina
Hospital Iturraspe
Santa Fe, Argentina
Hospital Universitario Austral
Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina
Hospital Italiano de Buenos Aires
Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina
Centro de Educacion Medica e Investigaciones Clinicas "Norberto Quirno" (CEMIC)
Buenos Aires, Ciudad Autonoma de BuenosAires, Argentina
St Vincents Hospital Melbourne - PPDS
Fitzroy, Victoria, Australia
Frankston Hospital
Frankston, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Paracelsus Medizinische Privatuniversitat
Salzburg, Austria
Medizinische Universitat Wien (Medical University of Vienna)
Vienna, Austria
Klinikum Wels-Grieskirchen GmbH
Wels, Austria
Universitatsklinikum Innsbruck
Innsbruck, Tyrol, Austria
Universitair Ziekenhuis Brussel - PIN
Brussels, Brussels Capital, Belgium
UZ Brussel
Brussels, Brussels Capital, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Brussels Capital, Belgium
HEMORIO - Unidade de Pesquisa Clinica
Rio de Janeiro, Brazil
Instituto Nacional de Cancer
Rio de Janeiro, Brazil
Showing 40 of 275 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.